|

PD-L1 Targeting Molecular Imaging of Solid Tumors

RECRUITINGN/ASponsored by Peking University Cancer Hospital & Institute
Actively Recruiting
PhaseN/A
SponsorPeking University Cancer Hospital & Institute
Started2021-07-20
Est. completion2024-11
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04629326

Summary

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* 1\. Aged \>18 years old; ECOG 0 or 1;
* 2\. Patients with Gastrointestinal tumors;
* 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
* 4\. life expectancy \>=12 weeks.

Exclusion Criteria:

* 1\. Significant hepatic or renal dysfunction;
* 2\. Is pregnant or ready to pregnant;
* 3\. Cannot keep their states for half an hour;
* 4\. Refusal to join the clinical study;
* 5\. Suffering from claustrophobia or other mental diseases;
* 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Conditions2

CancerGastrointestinal Tumors

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.